The Mark Foundation’s inaugural Scientific Advisory Committee comprises seven distinguished scientists who are recognized as key thought leaders in cancer research. With specialties in epigenetics, cancer genomics, stem cell biology, immunotherapy and more, this Committee will conduct peer review of all scientific grant proposals and provide guidance regarding The Mark Foundation’s overall funding strategies and investment opportunities. Leukemia expert Ross L. Levine, MD of Memorial Sloan Kettering Cancer Center will helm the Committee whose members will serve a three-year term.
“We are thrilled to have Ross lead this exceptional team of experts,” said Michele Cleary, PhD, Chief Executive Officer of The Mark Foundation. “Our partnership with them in this endeavor will be critical to achieving the impact for cancer patients and their families to which The Mark Foundation aspires.” Read our full press release here.